Founded in Vigevano in 2017 as an innovative medtech start-up
Born to solve a problem that costs human lives
PoloPlasma was founded to address airborne microbiological contamination in hospitals and critical environments through scientifically validated cold plasma technology.
2017
Founded in Vigevano, Italy
2
Patents filed for the technology
TRL9
Validated prototype installed
Clinical field validation
24/7 testing in a real surgical theatre
OUR STORY
Da un problema urgente a una tecnologia brevettata
Four key milestones in eight years of research, development and field validation.
2017 — The beginning
The birth of PoloPlasma
After many years facing the long‑standing issue of hospital microbiological contamination, especially in operating rooms, and the ongoing problem of healthcare‑associated infections (HAI), at the end of 2017 PoloPlasma S.r.l. was founded as an innovative start‑up.
Together with several colleagues and friends, the idea took shape: to develop an automatic decontamination system capable of tackling this problem, based on a cold plasma process applied to ambient air, at low pressure and temperature, with a dynamic behavior differing between day and night and with a process that is technically effective, repeatable and safe.
Limited company founded
Innovative start‑up
Vigevano (PV)
Bicocca University — Physics
University of Milan — Microbiology
ISO 8 cleanroom
2018–2020 — Research and development
First development with the university and first field experience
The initial development stemmed from a collaboration with the University of Milano‑Bicocca, Institute of Physics, and the University of Milan, Institute of Microbiology. This was followed by an initial validation in an ISO 8 pharmaceutical industrial cleanroom, with excellent results in combination with the existing ventilation system.
2021–2024 — Exploration and strategic focus
Experience in various industrial and pharmaceutical sectors
Several prototypes were built and used to explore three application areas: decontamination in the hospital‑healthcare sector, food preservation in modified‑atmosphere chambers and sterilization in pharmaceutical isolators and sterilizers for surgical instruments.
The experience gained led to concentrating all research on hospital decontamination in surgical theatres and on dry sterility, with the food sector being phased out.
The strategic decision to focus on hospital decontamination in operating rooms proved decisive for the development of PLASMAIR.
PLASMAIR — product name
2 registered patents
TRL9 prototype
Ce.Me.Di. Turin — Lifenet
2024–2026 — Commercialization
PLASMAIR is born: TRL9 prototype installed at Ce.Me.Di. in Turin (Lifenet Group)
Through a collaboration between PoloPlasma and Ssprogetti, Futura Innovazione was founded, securing public funding for the development of the hospital project and for the Italian distribution of the product, which was given the name PLASMAIR.
The pre‑commercial TRL9 prototype was installed in a surgical theatre. Two patents were obtained covering the decontamination and sterilization processes, protecting the original process. The procedure to obtain CE marking was launched in order to begin commercialization.
The pre‑commercial TRL9 prototype was installed in a surgical theatre. Two patents were obtained covering the decontamination and sterilization processes, protecting the original process. The procedure to obtain CE marking was launched in order to begin commercialization.
The latest TRL9 prototype operated for 6 consecutive months, 24/7, in a non‑classified surgical theatre, achieving ISO 7 classification at the Ce.Me.Di. outpatient clinic in Turin, with a reduction of −85% in bacterial load and −50% in airborne particles.
COLLABORATIONS AND PARTNERSHIPS
The network that made PLASMAIR possible
SCIENTIFIC RESEARCH
University of Milano‑Bicocca — Institute of Physics
Development and characterization of the SDBD plasma reactor. Study of the reactive species generated and optimization of the air ionization process.
SCIENTIFIC RESEARCH
University of Milan — Microbiology
Microbiological validation of the process. Efficacy tests on bacteria, viruses and fungal spores under controlled laboratory and cleanroom conditions.
INDUSTRIAL PARTNERSHIP
Ssprogetti — Futura Innovazione
Creation of Futura Innovazione for the commercial development and Italian distribution of PLASMAIR. Public funding obtained for the hospital project.
CLINICAL VALIDATION
Ce.Me.Di. di Torino — Gruppo Lifenet
Site where the latest TRL9 prototype was installed in a controlled healthcare environment, used for continuous testing as clinical validation of the final product.
INDUSTRIAL VALIDATION
Pharmaceutical ISO 8 cleanroom
First field validation in a controlled pharmaceutical environment, with excellent results in combination with the existing mechanical ventilation (VMC) system.
Do you want to become an international distribution partner for PLASMAIR?